These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 7319129)
1. Quantitative thermal imaging to assess inositol nicotinate treatment for Raynaud's syndrome. Ring EF; Porto LO; Bacon PA J Int Med Res; 1981; 9(6):393-400. PubMed ID: 7319129 [No Abstract] [Full Text] [Related]
2. Quantitative thermographic assessment of inositol nicotinate therapy in Raynaud's phenomena. Ring EF; Bacon PA J Int Med Res; 1977; 5(4):217-22. PubMed ID: 881094 [TBL] [Abstract][Full Text] [Related]
3. An experimentally controlled evaluation of the effect of inositol nicotinate upon the digital blood flow in patients with Raynaud's phenomenon. Holti G J Int Med Res; 1979; 7(6):473-83. PubMed ID: 391622 [TBL] [Abstract][Full Text] [Related]
4. [Thermography in evaluating therapy in Raynaud's disease]. Litmanovitch J; Shilo R; Chayen M Harefuah; 1972 Jun; 82(11):503-6. PubMed ID: 5068900 [No Abstract] [Full Text] [Related]
5. [Experience with the medical treatment of chronic cerebrovascular insufficiency: bamethan and inositol nicotinate versus placebo]. Cucinotta D; Silvestrini C; Mancini M; Maini C; Passeri M G Clin Med; 1981 May; 62(5):339-50. PubMed ID: 6115790 [No Abstract] [Full Text] [Related]
6. Treatment of peripheral arterial insufficiency with inositoli nicotinas (Hexanicit). Hentzer E Scand J Clin Lab Invest Suppl; 1967; 99():226-32. PubMed ID: 4862834 [No Abstract] [Full Text] [Related]
7. A plethysmographic study of the effect of tetranicotinoylfructose (Bradilan) on digital blood flow in primary and secondary Raynaud's phenomenon. Antcliff AC; Bouhoutsos J; Martin P; Morris T Angiology; 1974 May; 25(5):312-6. PubMed ID: 4823806 [No Abstract] [Full Text] [Related]
9. A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease. Sunderland GT; Belch JJ; Sturrock RD; Forbes CD; McKay AJ Clin Rheumatol; 1988 Mar; 7(1):46-9. PubMed ID: 3044673 [TBL] [Abstract][Full Text] [Related]
10. [The vasoprostan treatment of patients with Raynaud's syndrome]. Alekperov RT; Mach ES; Guseva NG Ter Arkh; 1997; 69(8):22-3. PubMed ID: 9381386 [No Abstract] [Full Text] [Related]
11. [The association of kallikrein and inositol hexanicotinate in the therapy of peripheral obliterating arteriopathy]. D'Ayala Valva G Recenti Prog Med; 1966 Jun; 40(6):XIX-XXXVI. PubMed ID: 6014405 [No Abstract] [Full Text] [Related]
12. [Thermography of collagen diseases with Raynaud's phenomenon]. Watanabe I; Sagawa A; Baba Y; Atsumi T; Jodo S; Amazaki Y; Nakabayashi T; Mukai M; Fujisaku A; Nakagawa S Ryumachi; 1991 Apr; 31(2):167-74. PubMed ID: 1925795 [TBL] [Abstract][Full Text] [Related]
13. [A study of Raynaud's syndrome using dynamic infrared thermography]. Shcherbakov AB; Koreneva LG; Markov AG Revmatologiia (Mosk); 1990; (2):7-11. PubMed ID: 2218268 [TBL] [Abstract][Full Text] [Related]
14. Methods of evaluating Raynaud's phenomenon for the purpose of pharmacotherapeutic research. Wouda AA Vasa Suppl; 1987; 18():32-9. PubMed ID: 3474798 [No Abstract] [Full Text] [Related]
15. [Contact plate thermography with cold provocation tests for the diagnosis of Raynaud's phenomenon]. Happersberger R; Heidrich H Vasa; 1990; 19(2):112-8. PubMed ID: 2371784 [TBL] [Abstract][Full Text] [Related]
16. Prostaglandin E1 vasospastic disease and thermography. Kyle V; Parr G; Salisbury R; Thomas PP; Hazleman B Ann Rheum Dis; 1985 Feb; 44(2):73-8. PubMed ID: 3977414 [TBL] [Abstract][Full Text] [Related]
17. [Recent advances in Raynaud's syndrome]. Klein-Weigel P Dtsch Med Wochenschr; 2012 Mar; 137(13):622-4. PubMed ID: 22434167 [No Abstract] [Full Text] [Related]